ANTX: שווי שוק לרווח נקי מותאם קצב צמיחה AN2 Bio

סמל ולוגו של המותג AN2 Bio (ANTX)

The development of new antibiotics in the US coincides with a period of R&D portfolio restructuring and management adaptation for AN2 Therapeutics, Inc. (ANTX). The weighted PEG ratio on the GURU.Markets dynamic chart reflects the current valuation, where the 0.00 mark indicates the asset's market value level. Looking ahead, AN2 Therapeutics, Inc. (ANTX) aims to expand its range of drugs against rare pulmonary infections and commercialize epetraronal.

ANTX (an2therapeutics.com) היסטוריית מכפיל PEG מ-28.04.2023 עד 15.11.2026

פילוחים אנליטיים של חברת AN2 Therapeutics Inc (ANTX)

אנליטיקה מסכמת של החברה:AN2 Bio
מוצר סדרתי של AN2 Therapeutics

AN2 Therapeutics, Inc. (ANTX) develops antibiotics for the treatment of pulmonary infections, leveraging R&D patent protection. By analyzing the normalized PEG ratio, an investor compares the company's market value with its earnings growth. This metric divides the P/E ratio by the revenue growth rate, revealing any disproportion between price and expansion. A value below one signals an undervaluation of the scalable business's potential, allowing for the efficient identification of undervalued assets with high leverage.